Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
Fatty Liver Alliance: Advancing Awareness and Advocacy for MASLD and MASH
Steatotic Liver Disease (MASLD/MASH)
Here are a Few of Our Recent Blog Posts
Case in Point: Joy’s Journey Through MASH - How Experts Would Manage This Complex Patient
This expert panel discussion highlighted the multidisciplinary, patient-centered approach needed to manage complex MASH cases like Joy’s, emphasizing practical strategies across lifestyle, pharmacotherapy, mental health, and system-level collaboration to drive meaningful, sustainable outcomes.
Can GLP-1s Change the Trajectory of MASLD?
Rethinking “Business as Usual”
The projections from the JAMA Network Open study represent a business-as-usual trajectory—a status quo where awareness remains low, screening rates are modest, and treatment access remains limited. But the world is already changing:
- GLP-1s are being prescribed more widely for weight and glycemic control.
- Clinicians are becoming more aware of MASLD, especially in patients with obesity, diabetes, and metabolic syndrome.
- Non-invasive diagnostics are expanding into primary care and endocrinology settings.
With these trends in motion, the real future of MASLD may diverge from the grim path laid out in the modeling study.
From Awareness to Action: Lifestyle Tools to Take on MASH
Why Lifestyle Matters More Than Ever
We’re in an era where metabolic dysfunction-associated steatohepatitis (MASH) affects millions globally, and treatment options are still evolving. But one thing remains constant: lifestyle modification is the foundation of care. Professor Zelber-Sagi emphasized that weight loss, dietary changes, and physical activity have the most robust evidence in reversing disease progression..
Beyond Lifestyle: The New Era of Targeted Therapies for MASH
Cracking the Code on MASH: Risk Stratification and Real-World Management
The future of MASH (Metabolic dysfunction-Associated Steatohepatitis) treatment is here—and it's far more hopeful than ever before. At Liver Connect 2025 in San Antonio, Dr. Manal Abdelmalek from the Mayo Clinic delivered a dynamic and insightful overview of the current and emerging therapies transforming care for patients living with MASH.
Lifestyle Is Still the Foundation—But We Need More
Dr. Abdelmalek emphasized that no matter how promising the pharmacologic pipeline becomes, lifestyle modification remains central. However, real-world limitations—challenges with long-term adherence, comorbidities, and systemic barriers—mean that medication is a necessary complement for many.
Cracking the Code on MASH: Risk Stratification and Real-World Management
Cracking the Code on MASH: Risk Stratification and Real-World Management
Cracking the Code on MASH: Risk Stratification and Real-World Management
MASH is no longer a future concern—it’s a present reality. Millions of patients are affected, and it’s up to all of us—clinicians, advocates, and policymakers—to respond.
At the 2025 Desert Liver Conference, Dr. Eric Lawitz offered a masterclass in understanding the disease, from its evolving terminology to its pathophysiology, screening strategies, and real-world management. If you're a primary care provider, endocrinologist, cardiologist, or any clinician involved in chronic disease care—this affects you.
Finding the Right Patients: NITs and the Future of MASH Screening
Cracking the Code on MASH: Risk Stratification and Real-World Management
Cracking the Code on MASH: Risk Stratification and Real-World Management
As new therapies for Metabolic dysfunction-Associated Steatohepatitis (MASH) emerge, the pressure is on to find the right patients at the right time—before irreversible liver damage sets in. At the 2025 Desert Liver Conference, Dr. Meena Bansal, a leading hepatologist and clinical researcher from New York City, delivered a compelling talk on screening high-risk populations and optimizing the use of non-invasive tests (NITs) to identify patients with at-risk MASH.
Expanding the MASH Arsenal: How GLP-1 Receptor Agonists Could Complement MASH Treatment
Expanding the MASH Arsenal: How GLP-1 Receptor Agonists Could Complement MASH Treatment
This important new review by Alkhouri et al. highlights the growing potential of GLP-1 receptor agonists (GLP-1RAs) as a valuable therapeutic tool for patients with MASLD and MASH, particularly those with multiple cardiometabolic comorbidities.
The authors provide a compelling overview of the pleiotropic effects of GLP-1RAs and their relevance to gastroenterologists navigating this evolving clinical landscape.
The Role of Medical Education in Addressing MASLD
Expanding the MASH Arsenal: How GLP-1 Receptor Agonists Could Complement MASH Treatment
A Call to Action: Shaping the Future of Medicine
The statistics are clear—MASLD is on the rise, and without urgent intervention, its impact will only worsen. Addressing this crisis requires more than just awareness; it demands a fundamental shift in how we educate future physicians.
Monitoring Treatment Response in MASH
Non-Invasive Tests (NITs) for MASLD/MASH
Nonalcoholic steatohepatitis (NASH), now classified under metabolic dysfunction-associated steatohepatitis (MASH), is a progressive liver disease that can lead to fibrosis, cirrhosis, and severe liver complications. The challenge in managing MASH has always been how to effectively monitor patient response to treatment without relying on invasive liver biopsies.
At the recent Desert Liver Conference, Dr. Mazen Noureddin provided valuable insights into non-invasive methods for tracking treatment response, discussing both clinical trial applications and real-world practice.
Non-Invasive Tests (NITs) for MASLD/MASH
Non-Invasive Tests (NITs) for MASLD/MASH
Summary of Dr. Naim Alkhouri’s Presentation on Non-Invasive Tests (NITs) for MASLD/MASH Screening in Clinical Practice from the Desert Liver Conference 2025.
Dr. Naim Alkhouri, along with Dr. Mazen Noureddin and Dr. Meena Bansal (summaries of their presentations to follow), discussed the clinical perspective on non-invasive tests (NITs) for identifying and managing MASLD/MASH patients, particularly in primary care and diabetes clinics.
Understanding MASLD and MASH: Why Your Liver Health Matters More Than You Think
Dr. Supriya Joshi emphasizes that MASLD and MASH are common yet often overlooked conditions affecting nearly 40% of the global population. She highlighted that early detection through simple tests like FIB-4 and FibroScan is crucial, as MASH can lead to liver fibrosis, cirrhosis, and even liver cancer if left untreated.
However, she provides hope by demonstrating that MASLD and MASH are preventable and reversible through lifestyle changes, weight management, and emerging pharmaceutical treatments.
Taking Action: Current and Emerging Treatments for MASH
If you’ve been diagnosed with Metabolic dysfunction-Associated Steatohepatitis (MASH), you may have felt frustrated by the lack of available treatment options in the past. But 2024 is a breakthrough year, and the future is looking brighter than ever!
In this final installment of the Liver Insights 2 series, we will walk you through the latest treatments, exciting new developments on the horizon, and most importantly, what you can do to take control of your liver health today.
Urgent Call to Action
Fatty Liver Alliance in the News
The Fatty Liver Alliance a Canada-based advocacy group, is calling for supporters to sign a petition asking Madrigal Pharmaceuticals to apply to Canadian regulators for approval of Rezdiffra (resmetirom), the company’s oral therapy for metabolic dysfunction-associated steatohepatitis (MASH).
https://liverdiseasenews.com/news/nonprofits-petition-aims-expedite-canadian-access-rezdiffra/
Canadians Deserve Equal Access to Life-Saving Liver Treatment - Sign the Petition Now!
Today, we're taking a crucial step forward in advocating for Canadians diagnosed with MASH (Metabolic dysfunction-Associated Steatohepatitis).
We've launched a petition asking Madrigal Pharmaceuticals to apply to Health Canada, so that Canadians can have access to Rezdiffra—a vital treatment for MASH.
Your support is essential! Please take a moment to sign our petition and share this with your network. Together, we can make a difference!
🔗 Sign the Petition Here: https://globalliver.salsalabs.org/petitionrezdiffracanada
🔗 Read Our Media Release: Urgent Call to Action: Canadians Deserve Equal Access to Life-Saving Liver Treatment--Sign the Petition Now!
Thank you for standing with us in this important cause.
Our Team
Our History
Our History
Our amazing team of full and part-time volunteers are committed to helping others. We take our convictions and turn them into action. Think you would be a good fit? Get in touch for more information!
Our History
Our History
Our History
Our nonprofit charity was created to build a supportive community. Canada’s population is about 38.8M with an estimated 15.5M who may have Metabolic Dysfunction Associated Liver Disease (MASLD) (formerly NAFLD). Of those, an estimated 20% - 25% will progress to cirrhosis and suffer with Metabolic-dysfunction Associated Steatohepatitis (MASH) (formerly NASH).
Our Mission
Our History
Our Mission
We raise awareness about the risks, causes and complications of fatty liver disease and help those already diagnosed with MASLD or MASH by advocating for access to approved treatments and care.
I want to get involved!
Your support and contributions will enable our Registered Charity to meet our goals and your generous donations will fund our mission and purpose. Charity #79690 4704 RR0001
We will issue a tax receipt for donations of $18.00 or greater.
**Best option for us, is e-transfer to donations@fattyliver.ca
In the comment section, we need your full name and address so we can issue a tax receipt. Other payment options below.
Collaboration: Global Liver Institute-Liver Action Network
